Economics and the new generation of targeted therapies for non-small cell lung cancer.
作者信息
Ramsey Scott D
出版信息
J Natl Cancer Inst. 2010 Mar 3;102(5):287-8. doi: 10.1093/jnci/djq012. Epub 2010 Feb 16.
PMID:20160167
Abstract
摘要
相似文献
1
Economics and the new generation of targeted therapies for non-small cell lung cancer.
J Natl Cancer Inst. 2010 Mar 3;102(5):287-8. doi: 10.1093/jnci/djq012. Epub 2010 Feb 16.
2
Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
J Natl Cancer Inst. 2010 Mar 3;102(5):298-306. doi: 10.1093/jnci/djp518. Epub 2010 Feb 16.
3
Gefitinib for advanced or metastatic non-small cell lung cancer.
Issues Emerg Health Technol. 2004 Apr(55):1-4.
4
Clinical and economic review of erlotinib in non-small-cell lung cancer.
Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):411-23. doi: 10.1586/erp.12.42.
5
Erlotinib for the treatment of relapsed non-small cell lung cancer.
Health Technol Assess. 2009 Jun;13 Suppl 1:41-7. doi: 10.3310/hta13suppl1/07.
6
Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
J Med Econ. 2011;14(2):159-66. doi: 10.3111/13696998.2011.557457. Epub 2011 Feb 2.
7
Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence.
Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):409-16. doi: 10.1586/erp.09.49.
8
Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
J Natl Cancer Inst. 2009 Aug 5;101(15):1039-41. doi: 10.1093/jnci/djp243. Epub 2009 Jul 28.
9
[Targeted therapies for lung cancer].
Rinsho Ketsueki. 2008 Aug;49(8):616-21.
10
Iressa : first angiogenesis inhibitor approved for the treatment of advanced NSCLC.
Expert Rev Anticancer Ther. 2003 Jun;3(3):257. doi: 10.1586/14737140.3.3.257.
Zotero 插件